Drugs News and Research

RSS

Cell-tracking software speeds drug development

Time is money, especially in the race to discover new anti-inflammatory drugs and bring them to market.

13 Dec 2007

Statins taken after stroke may increase risk of hemorrhagic stroke

People taking cholesterol-lowering drugs such as atorvastatin after a stroke may be at an increased risk of hemorrhagic stroke, or bleeding in the brain, a risk not found in patients taking statins who have never had a stroke.

13 Dec 2007

Secret lives of enzymes revealed

In a new study in Nature, Brandeis University Howard Hughes Medical Investigator Dr. Dorothee Kern and collaborators pull back the curtain on the secret lives of enzymes, the ubiquitous proteins that catalyze chemical reactions in the cell.

13 Dec 2007

Carbamazepine based drugs to include new advice for patients with Asian ancestry

The U.S. Food and Drug Administration today announced that the manufacturers of drugs containing the active ingredient carbamazepine have agreed to add to the drugs' labeling a recommendation that, before starting therapy with the drugs, patients with Asian ancestry get a genetic blood test that can identify a significantly increased risk of developing a rare, but serious, skin reaction.

13 Dec 2007

Cancer stem cells may be cause of brain tumors

Expert available for comment on "Cancer Stem Cells" symposium at American Society of Hemotology (ASH) meeting, led by Dr. Andrew Schafer, chairman of medicine, NewYork-Presbyterian/Weill Cornell, and president, ASH.

13 Dec 2007

Telmisartan potent against stroke

Telmisartan, a drug widely used to help control blood pressure, may have uniquely potent activity in preventing stroke, according to a new study conducted in an animal model.

13 Dec 2007

Velcade, lenalidomide and dexamethasone combo show promise for multiple myeloma

A new combination of bortezomib (Velcade) and two other drugs is showing a very high response rate in patients newly diagnosed with multiple myeloma, a team headed by Dana-Farber Cancer Institute investigators reported at the annual meeting of the American Society of Hematology.

13 Dec 2007

Scientists develop new drug to outflank cancer resistance

A new drug has shown promising results against breast and prostate cancer cells and tumours that are resistant to conventional hormone-based treatments, according to research published in the British Journal of Cancer.

12 Dec 2007

Novel technique using computer modeling identifies potential side effects of pharmaceuticals

Early identification of adverse effects of drugs before they are tested in humans is crucial in developing new therapeutics, as unexpected effects account for a third of all drug failures during the development process.

12 Dec 2007

Lethal human H5N1 influenza virus Replikin gene still upregulated

Replikins Ltd. has announced its latest findings regarding the virus replikin count in human H5N1 influenza virus. The company's software-driven analysis has found that the prevalence of these sequences has remained high in Indonesia; in addition, higher counts now have been found in China.

12 Dec 2007

Epigenomic test that could improve treatment for specific gastric cancers

A study by researchers at the John Wayne Cancer Institute at Saint John's Health Center in a recent issue of Journal of Clinical Oncology identifies activation of the enzyme COX-2 in gastric cancer tumors as a prognostic indicator for poor outcome.

12 Dec 2007

Bosutinib safe, effective for chronic myelogenous leukemia

A new drug for chronic myelogenous leukemia works for patients who have developed resistance to frontline therapy and causes fewer side effects than other medications in its class, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports at the 49th annual meeting of the American Society of Hematology.

12 Dec 2007

Popular heartburn drug given the all clear

Concerns that a drug used to treat stomach conditions such as heartburn could cause heart problems have been laid to rest by a comprehensive review.

11 Dec 2007

Study finds disease management programs improve the quality of health care

Disease management programs that help guide the care of patients with chronic health problems appear to improve the quality of health care, but there is little evidence that such efforts actually save money, according to a study issued by the RAND Corporation.

10 Dec 2007

New test for targeted therapy in acute myeloid leukemia

Oregon Health & Science University Cancer Institute researcher Jeff Tyner, Ph.D., has created a way to identify proteins that are candidates for targeted therapy in acute myeloid leukemia using an assay that yields results in just four days.

10 Dec 2007

New drug candidate knocks out resistant form of chronic myeloid leukemia

Oregon Health & Science University Cancer Institute researchers have found a new, experimental drug candidate it to be effective against a highly resistant mutation in chronic myeloid leukemia (CML).

10 Dec 2007

Missing protein provides clue to ovarian cancer drug success

Scientists have discovered a protein which could improve the success rate of the tumour shrinking drug paclitaxel, in the treatment of ovarian cancer, a study reveals in Cancer Cell.

10 Dec 2007

MDs' reactions to pharma marketing influenced by brand, side effects

A study of pharmaceutical companies' marketing to physicians shows that doctors are most influenced by brand preference and marketing that addresses the problems of drugs with many side effects, according to the Management Insights feature in the current issue of Management Science, the flagship journal of the Institute for Operations Research and the Management Sciences (INFORMS).

10 Dec 2007

Keeping at-risk cells from developing cancer

Researchers at Johns Hopkins have discovered that cancers arising from epigenetic changes - in this case the inappropriate activation of a normally silent gene - develop by becoming addicted to certain growth factors.

10 Dec 2007

Growth factor receptor affects prostate cancer progression

Breeding mice with a gene for a cellular receptor that can be turned on and off-at will-not only enabled researchers at Baylor College of Medicine in Houston to show how prostate cancer progresses, but also provides a model for studying when a drug targeting a gene will have an effect on the cancer.

10 Dec 2007